JMI-105

• Description:

  JMI-105 is a potent PfFP-2 (Plasmodium falciparum falcipain-2 protease) inhibitor. JMI-105 inhibits the growth of CQS (3D7; IC50=8.8 µM) and CQR (RKL-9; IC50=14.3 µM) strains of P. falciparum. JMI-105 significantly decreases parasitemia and prolonged host survival in a murine model with P. berghei ANKA infection. JMI-105 has the potential to be used as an anti-malarial agent[1].

• UNSPSC:

  12352005

• Target:

  Parasite

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/jmi-105.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC (C1=CC=C (C) C (OCC2=CN (C3=CC=C (OC) C=C3) N=N2) =C1) C

• Molecular Formula:

  C20H23N3O2

• Molecular Weight:

  337.42

• References & Citations:

  [1]Uddin A, et al. Identification and structure-activity relationship (SAR) studies of carvacrol derivatives as potential anti-malarial against Plasmodium falciparum falcipain-2 protease. Bioorg Chem. 2020 Oct;103:104142.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Plasmodium

• CAS Number:

  2227315-30-0